Rhythm posted earnings per share of $‑0.73 for Q2, beating the $‑0.84 consensus estimate. The beat narrows the loss gap, reassuring investors as the company scales IMCIVREE revenue and advances the RM‑718 trial, supporting momentum in the rare obesity market.
Key Highlights
- IMCIVREE global sales rose 19% sequentially to $71.3 million in Q2
- RM-718 achieved a mean BMI reduction of -11.6% at 16 weeks in Phase 2 patients
- Cash, cash equivalents and short‑term investments stood at approximately $330.9 million
Rhythm Pharmaceuticals (NASDAQ: RYTM) delivered a quarterly revenue surge, posting $71.3 million from IMCIVREE sales, a 19% jump from the prior quarter, while earnings per share improved to $‑0.73 versus the $‑0.84 consensus. The boost stems from strong U.S. demand and expanding patient uptake, underscoring the commercial traction of its MC4R‑agonist portfolio.
$71.3M Revenue Surge
The company’s global IMCIVREE topline climbed to $71.3 million, with U.S. sales accounting for $51.0 million, a 38% sequential increase that lifted the U.S. contribution to 72% of total revenue. The sequential growth aligns with a greater than 20% rise in reimbursed patients worldwide, highlighting expanding market penetration. This revenue acceleration improves cash flow prospects, yet the heavier reliance on the U.S. market raises exposure to payer policy shifts, a risk that investors must weigh.
RM-718 Phase 2 Data
In the open‑label Phase 2 study of RM‑718, seven of eleven enrolled patients reached week 16 and recorded a mean body‑mass‑index decline of -11.6%, comparable to the -10.1% reductions observed with setmelanotide and bivamelagon in parallel trials. Adverse events were limited to injection‑site reactions, nausea, and vomiting, with only two mild cases of hyperpigmentation confined to the injection site. The data suggest RM‑718’s MC4R selectivity may mitigate the hyperpigmentation seen with earlier agents, positioning it as a next‑generation candidate for acquired hypothalamic obesity.
Demonstrated efficacy strengthens the pipeline, but the small sample size leaves uncertainty around broader applicability.
Market Reaction and Valuation
Short interest sits at 14% of shares outstanding with 13.7 days of average volume to cover, indicating a moderate level of bearish positioning. Investors must balance the upside from expanding IMCIVREE sales against the cash burn and the need for continued clinical success.
Upcoming Milestones
Further milestones include completing enrollment in the setmelanotide congenital hypothalamic obesity substudy and the Phase 1/2 Part D trial of RM‑718 in Prader‑Willi syndrome later this year, as well as a pending Japanese regulatory decision on IMCIVREE by year‑end. These events will test whether the recent commercial momentum can be sustained and whether the pipeline can deliver additional growth drivers.
Peers Moving on This News
- Immunovant Inc (IMVT) up 1.8%
- Vaxcyte Inc (PCVX) up 1.0%
- Immunitybio Inc (IBRX) down 5.5%
Analysis based on the Form 8-K filed 4 August 2026; figures verified against the filing and live market data.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.




_11_17_2026_20_37_58_946960.jpg)

Please wait processing your request...